High- vs. Low-Threshold Surfactant Re-treatment for Neonatal RDS • 1039

Surfactant administration in premature infants with RDS

Background. The significant advancement in the treatment of respiratory distress syndrome can be attributed to prenatal identification of high risk pregnancies, prevention of illness through antenatal care, prenatal administration of glucocorticoids, advancement in respiratory support and surfactant therapy. These measures resulted in the reduction of mortality and morbidity rates in preterm in...

Surfactant and RDS in premature infants.

RDS--CPAP or surfactant or both.

UNLABELLED There is mounting evidence that early continuous positive airway pressure (CPAP) from birth is feasible and safe even in very preterm infants. However, many infants will develop respiratory distress syndrome (RDS) and require surfactant treatment. Combining a non-invasive ventilation approach with a strategy for surfactant administration is important, but questions remain about the o...

Neonatal Respiratory Distress Syndrome and Its Treatment with Artificial Surfactant

Neonatal respiratory distress syndrome [4], previously called hyaline membrane disease, is a respiratory disease affecting premature newborns. Neonatal respiratory distress syndrome [4] involves shallow breathing, pauses between breaths that last a few seconds, or apnea, and a bluish tinge to the infant?s skin. The syndrome occurs when microscopic sacs called alveoli in infant lungs do not prod...

Neonatal Respiratory Distress Syndrome and Its Treatment with Artificial Surfactant

Neonatal respiratory distress syndrome [4], previously called hyaline membrane disease, is a respiratory disease affecting premature newborns. Neonatal respiratory distress syndrome [4] involves shallow breathing, pauses between breaths that last a few seconds, or apnea, and a bluish tinge to the infant?s skin. The syndrome occurs when microscopic sacs called alveoli in infant lungs do not prod...